Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01409174 | IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma | terminated | Phase 1 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | May 31, 2017 | clinicaltrials |
| NCT00658892 | Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma | completed | Phase 1 | 7 | Mayo ClinicOTHER | 1 | May 25, 2017 | clinicaltrials |
| NCT01843738 |
| Radiation Use During Vemurafenib Treatment |
| withdrawn |
| Phase 1 |
| 0 |
| University of UtahOTHER |
| 1 |
| May 24, 2017 |
| clinicaltrials |
| NCT01496807 | Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma | completed | Phase 1 | 31 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT00871481 | Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma | completed | Phase 1 / Phase 2 | 10 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 19, 2017 | clinicaltrials |
| NCT01760499 | Detection of Immune Cell Infiltration Into Melanomas Treated by PV-10, a Feasibility Study | completed | Phase 1 | 15 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 19, 2017 | clinicaltrials |
| NCT00940004 | Toll-like Receptor (TLR) Ligand Matured Dendritic Cell Vaccination in Melanoma Patients | completed | Phase 1 / Phase 2 | 20 | Radboud University Medical CenterOTHER | 1 | Apr 17, 2017 | clinicaltrials |
| NCT01530698 | Single-step Antigen Loading and TLR Activation of Dendritic Cells in Melanoma Patients | completed | Phase 1 / Phase 2 | 28 | Radboud University Medical CenterOTHER | 1 | Apr 17, 2017 | clinicaltrials |
| NCT02413827 | A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma | terminated | Phase 1 / Phase 2 | 9 | Celldex TherapeuticsINDUSTRY | 1 | Apr 7, 2017 | clinicaltrials |
| NCT01611675 | Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma | terminated | Phase 1 | 3 | Massachusetts General HospitalOTHER | 1 | Apr 6, 2017 | clinicaltrials |
| NCT01026324 | Dinaciclib in Treating Patients With Stage III-IV Melanoma | terminated | Phase 1 / Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Apr 4, 2017 | clinicaltrials |
| NCT01065467 | Panobinostat (LBH589) in Patients With Metastatic Melanoma | completed | Phase 1 | 16 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 28, 2017 | clinicaltrials |
| NCT01844674 | A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies | completed | Phase 1 | 18 | Hoffmann-La RocheINDUSTRY | 5 | Mar 20, 2017 | clinicaltrials |
| NCT00398073 | Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma | completed | Phase 1 | 35 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 16, 2017 | clinicaltrials |
| NCT01390818 | Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 146 | EMD SeronoINDUSTRY | 3 | Mar 7, 2017 | clinicaltrials |
| NCT00861406 | Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine | completed | Phase 1 | 38 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT00418496 | Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma | completed | Phase 1 | 17 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 20, 2017 | clinicaltrials |
| NCT00553306 | Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma | completed | Phase 1 / Phase 2 | 10 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT01121718 | NIR-Guided Sentinel Lymph Node Mapping in Melanoma | completed | Phase 1 | 26 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 3, 2017 | clinicaltrials |
| NCT02406183 | Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma | completed | Phase 1 | 13 | RadiotherapieOTHER | 1 | Jan 10, 2017 | clinicaltrials |
| NCT01984255 | A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients | terminated | Phase 1 | 3 | University of Texas Southwestern Medical CenterOTHER | 1 | Dec 29, 2016 | clinicaltrials |
| NCT01189383 | IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma | completed | Phase 1 / Phase 2 | 20 | Baylor Research InstituteOTHER | 1 | Dec 22, 2016 | clinicaltrials |
| NCT00705640 | Vaccine Therapy in Treating Patients With Advanced Melanoma(Mel48) | completed | Phase 1 | 45 | Craig L Slingluff, JrOTHER | 1 | Dec 16, 2016 | clinicaltrials |
| NCT00977145 | Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma(Mel 51) | terminated | Phase 1 | 11 | Craig L Slingluff, JrOTHER | 1 | Dec 16, 2016 | clinicaltrials |
| NCT01264731 | Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma(MEL53) | completed | Phase 1 | 4 | University of VirginiaOTHER | 1 | Dec 16, 2016 | clinicaltrials |
| NCT01765543 | A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf) | completed | Phase 1 | 27 | Hoffmann-La RocheINDUSTRY | 5 | Dec 15, 2016 | clinicaltrials |
| NCT02990416 | A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma | unknown | Phase 1 / Phase 2 | 63 | Virogen Biotechnology Inc.INDUSTRY | 1 | Dec 13, 2016 | clinicaltrials |
| NCT00256230 | Disulfiram in Patients With Metastatic Melanoma | completed | Phase 1 / Phase 2 | 7 | John P. FruehaufOTHER | 1 | Dec 8, 2016 | clinicaltrials |
| NCT01690377 | Natural Dendritic Cell Vaccines in Metastatic Melanoma Patients | completed | Phase 1 | 30 | Radboud University Medical CenterOTHER | 1 | Dec 8, 2016 | clinicaltrials |
| NCT02661100 | A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients | withdrawn | Phase 1 / Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Dec 7, 2016 | clinicaltrials |
| NCT00765921 | Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma | completed | Phase 1 | 40 | Massachusetts Eye and Ear InfirmaryOTHER | 1 | Dec 2, 2016 | clinicaltrials |
| NCT01888081 | A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for Treatment of Stage IV Melanoma | terminated | Phase 1 / Phase 2 | 2 | Virogen Biotechnology Inc.INDUSTRY | 1 | Nov 23, 2016 | clinicaltrials |
| NCT01950195 | SRS (Stereotactic Radiosurgery) Plus Ipilimumab | terminated | Phase 1 | 4 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 15, 2016 | clinicaltrials |
| NCT01522664 | A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma | completed | Phase 1 | 53 | Genentech, Inc.INDUSTRY | 2 | Nov 2, 2016 | clinicaltrials |
| NCT01765556 | A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma | withdrawn | Phase 1 | 0 | Hoffmann-La RocheINDUSTRY | 0 | Nov 2, 2016 | clinicaltrials |
| NCT01849666 | A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy | completed | Phase 1 | 2 | Hoffmann-La RocheINDUSTRY | 5 | Nov 2, 2016 | clinicaltrials |
| NCT01851824 | A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy | completed | Phase 1 | 9 | Hoffmann-La RocheINDUSTRY | 9 | Nov 2, 2016 | clinicaltrials |
| NCT01039844 | Study of Weekly LOC-paclitaxel Injection for Melanoma | terminated | Phase 1 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 27, 2016 | clinicaltrials |
| NCT01133977 | E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma | completed | Phase 1 / Phase 2 | 97 | Eisai Inc.INDUSTRY | 5 | Oct 10, 2016 | clinicaltrials |
| NCT01519323 | BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations | terminated | Phase 1 | 6 | Hoffmann-La RocheINDUSTRY | 10 | Oct 10, 2016 | clinicaltrials |
| NCT01522820 | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors | completed | Phase 1 | 18 | Roswell Park Cancer InstituteOTHER | 1 | Oct 4, 2016 | clinicaltrials |
| NCT01829971 | A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection | terminated | Phase 1 | 155 | Mirna Therapeutics, Inc.INDUSTRY | 2 | Sep 27, 2016 | clinicaltrials |
| NCT02862145 | Pharmacodynamics Study of MRX34, MicroRNA Liposomal Injection in Melanoma Patients With Biopsy Accessible Lesions(MRX34-102) | withdrawn | Phase 1 / Phase 2 | 0 | Mirna Therapeutics, Inc.INDUSTRY | 0 | Sep 27, 2016 | clinicaltrials |
| NCT01777776 | Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma. | terminated | Phase 1 / Phase 2 | 28 | Array BioPharmaINDUSTRY | 4 | Sep 13, 2016 | clinicaltrials |
| NCT01935453 | A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus to Treat Cancer | completed | Phase 1 | 18 | OrienGene Biotechnology Ltd.INDUSTRY | 1 | Sep 1, 2016 | clinicaltrials |
| NCT00580320 | Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma | completed | Phase 1 | 17 | Virginia Commonwealth UniversityOTHER | 1 | Aug 18, 2016 | clinicaltrials |
| NCT01278940 | Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Advanced Malignant Melanoma | completed | Phase 1 / Phase 2 | 31 | Oslo University HospitalOTHER | 0 | Aug 15, 2016 | clinicaltrials |
| NCT01585350 | A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients(MEL58) | completed | Phase 1 | 53 | Craig L Slingluff, JrOTHER | 1 | Aug 12, 2016 | clinicaltrials |
| NCT01846143 | Evaluation of a Multi-phosphopeptide Vaccine Plus PolyICLC in Participants With High Risk and Advanced Malignancies(Mel59) | completed | Phase 1 | 15 | Craig L Slingluff, JrOTHER | 1 | Aug 12, 2016 | clinicaltrials |
Data updated 23 days agoSource updated May 31, 2017source: clinicaltrials